Wednesday, 14 Nov 2018

You are here

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

  1. Canadian population studies shows that hyperlipidemia monitoring (mostly by PCPs) was poor for 5587 RA and 5613 controls; Lipids were measured in 56.6 and 59.5%, respectively     
  2. Metanalysis shows autoimmune disease significantly co-associated with psychosis (OR 1.26) - positive assoc w/ pernicious anemia (1.91), pemphigoid (1.90), psoriasis (1.70), celiac (1.53) & Graves Dz (1.33); but neg assoc for AS (0.72) & RA (0.65)
  3. Early Arthritis Clinic in Australia (2008-15) shows significant delays: from symptom onset to rheumatology review = 26.4 wks. Patient delay (8.7 wks) was the longest delay-predicted overall delay. GP  delays associated with lower disease severity & those at a socioeconomic disadvantage   
  4. 76/156 early RA pts in remission at 1 year were studied (including MRI) at baseline and at 12 months. Despite clinical remission a majority had MRI inflammation (43% synovitis, 39% BM edema, 9% tenosynovitis), and 33% showed MRI progression of bone erosions.
  5. Claims data study of GPA pts (214 children & 5,352 adults) showed hospitalizations 30% higher in children w/ GPA; who also had 2-3 fold higher rates of leukopenia (RR = 2.6), neutropenia (RR = 2.2) & hypogammaglobulinemia (RR = 3.7)
  6. NIH Rochester Epidemiology Project enrolled adults w/ LBP from 99-03 From 5304 pts with back pain, only 124 patients had new‐onset Inflam LBP (IBP). After 13.2 yrs, only 31% of IBP progressed to SpA; That IBP often resolves may explain difference betw prevalence of IBP (3–6%) & the prev of SpA (0.4–1.3%)   
  7. Testosterone use in USA tripled from 2001 - 2011, mostly men without clear indication. In late 2013 2 studies reported increased MI & CVA risk associated with testosterone use and since decreased 50%.
  8. The Diverse Fate of Seronegative Rheumatoid Arthritis  
  9. Defining Refractory RA by Biologic Use     
  10. IL-23 Inhibitor Fails in Ankylosing Spondylitis    
  11. Hydroxychloroquine Being Over-Dosed with New Guidelines?   
  12. Prescription Drugs and the Effect on Access to Biosimilars in the US   
  13. Upcoming ARTHROS Regional Meetings in Chicago, Nashville, Boston and Washington, DC  


The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

MMWR: Death by Firearms

The CDC's Morbidity and Mortality Weekly Report (MMWR) reports that during 2015–2016 there was a total of 27,394 firearm homicides and 44,955 firearm suicides among US residents, with 12% and 5% of events occuring in children 10–19 years.

RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)

Dr Jack Cush reviews the News and Journal reports from the past week on  Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.

E/M Guidelines: Right Road, Wrong Direction

Last July, the Centers for Medicare & Medicaid Services (CMS) proposed new E/M guidelines for office visits with physicians. It issued the final guidelines on November 1, with a few tweaks. Implementation was delayed until 2021 (from 2019), possibly due to overwhelming opposition from physicians.

RheumNow Week in Review – The Heart Attack Report (11.2.18)

Dr Jack Cush reviews the news and journal reports from the past week on

'These Results Are Astonishing': What We Heard at ACR 2018

"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.